Phase II/III Randomized Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred
Summary
3/16/2020 NOTE: Enrollment in Part 1 is complete. Part 2 is actively enrolling.
The purpose of this phase II/III study is to evaluate the safety and efficacy of SM-88 in patients with metastatic pancreatic cancer whose disease has progressed or recurred after two lines of prior systemic therapy.
General Information
NCT#: NCT03512756
Study ID: Tyme-88-Panc
Trial Phase: Phase II
Trial Sponsor: Tyme, Inc.
Therapies Used in This Trial: SM-88